Comparative Pharmacology
Head-to-head clinical analysis: CHIRHOSTIM versus SEROSTIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIRHOSTIM versus SEROSTIM.
CHIRHOSTIM vs SEROSTIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic tripeptide (l-prolyl-l-lysyl-l-phenylalanyl) that stimulates phagocytosis via activation of mononuclear phagocytes and polymorphonuclear leukocytes through binding to formyl peptide receptors (FPRs), enhancing chemotaxis, superoxide production, and bactericidal activity. Also enhances natural killer (NK) cell activity and modulates cytokine release (e.g., IL-1, IL-6, TNF-α).
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
Subcutaneous injection: 0.5 mg/kg once daily. Maximum dose: 40 mg/day.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
None Documented
None Documented
Terminal elimination half-life is 14-16 hours; clinically, steady-state is achieved in approximately 3-4 days.
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Primarily renal (70-85% as unchanged drug); biliary/fecal (10-20%) with enterohepatic recirculation.
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Category C
Category C
Growth Hormone
Growth Hormone